Business Wire - November 19, 2007

"The International Journal of TB and Lung Diseases is an important and well-respected publication covering all topics related to lung health," explained Neil Roth, President of Designer Diagnostics. "This article will act as an important stepping-stone in helping to build awareness about the importance of the Designer Diagnostics technology to isolate NTM," he added.

Recently, Dr. Narang presented the Designer Diagnostics test kit technology at the 38th Union World Conference on Lung Health in South Africa. Dr. Narang's presentation included information about the Designer Diagnostics test kits use in isolating NTM from clinical samples of 300 AIDS patients. The presentation also announced that for the first time ever on the Indian subcontinent, M. wolinskyi, a rapidly growing mycobacteria that is most commonly seen in post-traumatic wound infections and in immune-compromised patients, was successfully isolated in clinical samples.

"NTM infection is a serious health issue affecting millions of people each year in developing countries. Especially those countries with high incidence rates of HIV," commented Rik J. Deitsch, Chairman and CEO of Nutra Pharma Corporation. "We believe that the Designer Diagnostics test kits are vital for early diagnosis of the infection in patients, as the test kits are faster and less expensive than current tests. These kits are perfect for developing countries as they can be used in the field without the need for refrigeration and expensive lab equipment," he concluded.

About Nutra Pharma Corp.

Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's holding, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

http://www.NutraPharma.com

http://www.DesignerDiagnostics.com

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The upcoming article in the International Journal of TB and Lung Diseases should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

---

Contacts:

Nutra Pharma Corp., Boca Raton

Investor Relations:

David Isserman, 877-895-5647

ir@nutrapharma.com

071119
BW071119

Copyright © 2007 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .